Clinical trials: Depressed
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction
Trifecta Research Study
This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder…
- Conditions
- PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder
- Trial name
- NCT07717866
- Testing
- Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Axial Therapeutic Research
Depression - Major Depressive Disorder
EEG Prediction and Clinical Efficacy of tDCS in Major Depression
The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its…
- Trial name
- DM-TDCS-PREDIC (NCT07611773)
- Testing
- High-dose home-tDCS, Conventional home-tDCS
- Where
- Spain
- Volunteers
- 270 people
- Sponsor
- Ionclinics & Deionic SL
Depressive Disorder
rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure
This study is testing a process (rEEG)for selecting the most appropriate medication(s) to treat a patient's depression versus a control group being treated according to a standardized method, the modified Star*D Algorithm.
- Trial name
- NCT00437827
- Testing
- Star*D algorithm, rEEG-guided therapy
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- MYnd Analytics
Postpartum Depression
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
- Trial name
- NCT02285504
- Testing
- SAGE-547
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Postpartum Depression
Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression
This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial…
- Trial name
- NCT03924492
- Testing
- ZULRESSO (brexanolone) injection
- Sponsor
- Supernus Pharmaceuticals, Inc.
Bipolar Depression, Suicidal Ideation
NRX101 Glx Biomarker Validation Study
Subnormal level of Glutamate+Glutamine (Glx) in the Anterior Cingulate Cortex (ACC) of the brain has been associated with depression and PTSD.
- Trial name
- NRX-GLX (NCT03402152)
- Testing
- NRX-101, Lurasidone HCl
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
Fisher Wallace Neurostimulation & Depression Study
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator Device on Major Depressive Disorder using two 20-minute per day treatment sessions over eight weeks.
- Trial name
- NCT04541563
- Testing
- Fisher Wallace Cranial Electrotherapy Stimulator Device
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- ProofPilot
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Depressive Disorder, Major
A Study of GW856553X For the Treatment of Depression
GW856553 is a novel compound, currently in development for the treatment of Major Depressive Disorder (MDD), and other indications.
- Trial name
- NCT00569062
- Testing
- GW856553X
- Where
- 15 sites in Estonia, India and 1 more
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
- Trial name
- NCT05018013
- Testing
- Ammoxetine hydrochloride enteric-coated tablets, Duloxetine hydrochloride enteric-coated capsules
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder, MDD
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or…
- Conditions
- Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
- Trial name
- OBSERVER (NCT06512324)
- Testing
- Ampa One TMS System
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLC
Opioid-Induced Respiratory Depression, Postoperative Complications (Cardiopulmonary)
Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy
This study will evaluate whether quantitative pupillometry measurements can be used to identify children at risk for postoperative opioid-induced respiratory depression (OIRD) following tonsillectomy.
- Conditions
- Opioid-Induced Respiratory Depression, Postoperative Complications (Cardiopulmonary), Respiratory Complications Due to Anesthesia
- Trial name
- NCT07573150
- Testing
- Infrared Pupillometry
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- NeurOptics Inc
Cancer, Psycho-Oncology
What Impact Does an Initial Psycho-oncological Contact Have on People With Cancer?
When diagnosed with cancer, patients or their relatives may, if they wish, on the recommendation of the treatment team and/or in cases of high stress, seek psycho-oncological support.
- Trial name
- PICS (NCT07544446)
- Testing
- initial psycho-oncological contact, Standard
- Where
- 5 sites in Switzerland
- Volunteers
- 148 people
- Sponsor
- Lindenhofgruppe AG
Major Depression Disorder
Home tDCS for the Treatment of Major Depression.
The purpose of this multicentric randomized controlled trial is to compare the effectiveness and safety of home-based tDCS for the treatment of major depression versus tDCS treatment in a healthcare centre, and explore the…
- Trial name
- NCT07510880
- Testing
- Accelerated protocol of home Transcranial direct current stimulation, Conventional protocol of home Transcranial direct current stimulation, Conventional protocol of in person Transcranial direct current stimulation
- Where
- 3 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Ionclinics & Deionic SL
Postpartum Depression
Effect of Consuming a Combination of Probiotic Strains on Postpartum Depression
The objective of this trial is to evaluate the effect of consuming a combination of Lactobacillus during the pregnancy and lactation period on the incidence of postpartum depression.
- Trial name
- NCT06651424
- Testing
- Combination of Lactobacillus probiotics (no comercial)
- Where
- 3 sites in Spain
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Depression, COVID-19
Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks…
- Trial name
- TELESPHOR (NCT05323994)
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Servier Russia
Depressive Disorder, Major, Recurrence
Study Evaluating Venlafaxine ER in Recurrent Depression
The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
- Trial name
- NCT00046020
- Testing
- Venlafaxine ER
- Volunteers
- 1,096 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Suicide, Mental Health Disorder
A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- ViraSafeRCT (NCT07348666)
- Testing
- ViraSafe: Treatment pushes, BRITE
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ksana Health
Mood
The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention
The objective of this study is to investigate the efficacy and safety of MoodElite T-4003-1 on improving mood in a healthy adult population with mild to moderate depressive symptoms not eligible for therapeutic intervention.
- Trial name
- NCT05318456
- Testing
- MoodElite T-4003-1, Comparator
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Chenland Nutritionals Inc.
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.